PAracetamol Treatment in Hypertension: Effect on Blood Pressure (PATH-BP) Study (PATH-BP)
Primary Purpose
Blood Pressure
Status
Completed
Phase
Phase 4
Locations
United Kingdom
Study Type
Interventional
Intervention
Paracetamol
Placebo oral capsule
Sponsored by

About this trial
This is an interventional supportive care trial for Blood Pressure focused on measuring Blood pressure, Hypertension, Paracetamol, Acetaminophen
Eligibility Criteria
Inclusion Criteria:
- ≥18 years old, men or post-menopausal women (women with no periods for 12 months or more, or those who have had a surgical menopause)
- Treated hypertensive patients with an average daytime ambulatory blood pressure measurement (ABPM) <150/95mmHg on stable doses of one or more antihypertensive medication (at least one of which should be; an ACE inhibitor, angiotensin receptor blocker or diuretic) for 3 months, or untreated hypertensive patients with an average daytime ABPM ≥135/85 but <150/95.
Exclusion Criteria:
- History of ischaemic heart disease, cardiac failure, cerebrovascular disease, liver impairment (ALT/AST>50IU/L) or stage 3-5 chronic kidney disease.
- History of overdose or suicidal ideation
- Patients weighing <55kgs.
- Patients with chronic pain requiring treatment, with a known allergy to paracetamol, or concomitant use of non-steroidal anti-inflammatories , oral anticoagulants or corticosteroids.
Sites / Locations
- Clinical Research Centre, Western General Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Paracetamol
Placebo
Arm Description
paracetamol 1g (500mg x2) four times daily for 14 day period
Matched placebo control: hard gelatin placebo capsules containing Lactose Ph Eur. Taken for 14 days
Outcomes
Primary Outcome Measures
Systolic ambulatory blood pressure
Difference in mean daytime systolic ambulatory BP between the paracetamol and placebo treated groups.
Secondary Outcome Measures
Systolic clinic blood pressure
Difference in systolic clinic BP between the paracetamol and placebo treated groups.
Diastolic ambulatory blood pressure
Difference in mean daytime diastolic ambulatory BP between the paracetamol and placebo treated groups.
Full Information
NCT ID
NCT01997112
First Posted
November 21, 2013
Last Updated
October 1, 2019
Sponsor
University of Edinburgh
Collaborators
British Heart Foundation, National Health Service, United Kingdom
1. Study Identification
Unique Protocol Identification Number
NCT01997112
Brief Title
PAracetamol Treatment in Hypertension: Effect on Blood Pressure (PATH-BP) Study
Acronym
PATH-BP
Official Title
PAracetamol Treatment in Hypertension: Effect on Blood Pressure (PATH-BP) Study
Study Type
Interventional
2. Study Status
Record Verification Date
October 2019
Overall Recruitment Status
Completed
Study Start Date
January 2014 (undefined)
Primary Completion Date
June 4, 2019 (Actual)
Study Completion Date
October 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Edinburgh
Collaborators
British Heart Foundation, National Health Service, United Kingdom
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to examine if chronic paracetamol dosing increases blood pressure in patients with known high blood pressure.
Detailed Description
A prospective randomised, double-blind, crossover trial, comparing the effects of paracetamol 1g (500mg x2) four times daily with matched placebo on ambulatory and clinic BP, each given for 14 days, with a 14-day washout period.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Blood Pressure
Keywords
Blood pressure, Hypertension, Paracetamol, Acetaminophen
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
100 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Paracetamol
Arm Type
Active Comparator
Arm Description
paracetamol 1g (500mg x2) four times daily for 14 day period
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Matched placebo control: hard gelatin placebo capsules containing Lactose Ph Eur. Taken for 14 days
Intervention Type
Drug
Intervention Name(s)
Paracetamol
Other Intervention Name(s)
Acetaminophen
Intervention Type
Drug
Intervention Name(s)
Placebo oral capsule
Primary Outcome Measure Information:
Title
Systolic ambulatory blood pressure
Description
Difference in mean daytime systolic ambulatory BP between the paracetamol and placebo treated groups.
Time Frame
14 days
Secondary Outcome Measure Information:
Title
Systolic clinic blood pressure
Description
Difference in systolic clinic BP between the paracetamol and placebo treated groups.
Time Frame
14 days
Title
Diastolic ambulatory blood pressure
Description
Difference in mean daytime diastolic ambulatory BP between the paracetamol and placebo treated groups.
Time Frame
14 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
≥18 years old, men or post-menopausal women (women with no periods for 12 months or more, or those who have had a surgical menopause)
Treated hypertensive patients with an average daytime ambulatory blood pressure measurement (ABPM) <150/95mmHg on stable doses of one or more antihypertensive medication (at least one of which should be; an ACE inhibitor, angiotensin receptor blocker or diuretic) for 3 months, or untreated hypertensive patients with an average daytime ABPM ≥135/85 but <150/95.
Exclusion Criteria:
History of ischaemic heart disease, cardiac failure, cerebrovascular disease, liver impairment (ALT/AST>50IU/L) or stage 3-5 chronic kidney disease.
History of overdose or suicidal ideation
Patients weighing <55kgs.
Patients with chronic pain requiring treatment, with a known allergy to paracetamol, or concomitant use of non-steroidal anti-inflammatories , oral anticoagulants or corticosteroids.
Facility Information:
Facility Name
Clinical Research Centre, Western General Hospital
City
Edinburgh
State/Province
City Of Edinburgh
ZIP/Postal Code
EH4 2XU
Country
United Kingdom
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Citations:
PubMed Identifier
35130054
Citation
MacIntyre IM, Turtle EJ, Farrah TE, Graham C, Dear JW, Webb DJ; PATH-BP (Paracetamol in Hypertension-Blood Pressure) Investigators*. Regular Acetaminophen Use and Blood Pressure in People With Hypertension: The PATH-BP Trial. Circulation. 2022 Feb 8;145(6):416-423. doi: 10.1161/CIRCULATIONAHA.121.056015. Epub 2022 Feb 7.
Results Reference
derived
Learn more about this trial
PAracetamol Treatment in Hypertension: Effect on Blood Pressure (PATH-BP) Study
We'll reach out to this number within 24 hrs